C-Reactive Protein Induces Tau Hyperphosphorylation via GSK3β Signaling Pathway in SH-SY5Y Cells

Journal of Molecular Neuroscience

Volumn 56, Issue 2, 2015, Pages 519-527

  Guo, Haibiao ^a   Wang, Haitao ^a   Wang, Canmao ^a   Cheng, Yufang ^a   Zou, Zhengqiang ^a   Li, Yiwen ^a   Wu, Jingang ^a   Xu, Jiangping ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer s disease (AD); C reactive protein (CRP); Glycogen synthase kinase 3 beta (GSK3 ); Neurofibrillary tangles (NFTs); Tau

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; C REACTIVE PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN KINASE B; TAU PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MITOGEN ACTIVATED PROTEIN KINASE P38;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; INTERVENTION STUDY; INVESTIGATIVE PROCEDURES; MTT ASSAY; NEUROBLASTOMA CELL; NEUROTOXICITY; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; DRUG EFFECTS; METABOLISM; NERVE CELL; PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; C-REACTIVE PROTEIN; CELL LINE, TUMOR; GLYCOGEN SYNTHASE KINASE 3; HUMANS; NEURONS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 84930482724     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-015-0572-z     Document Type: Article

References (38)

1. Abad MA, Enguita M, DeGregorio-Rocasolano N, Ferrer I, Trullas R (2006) Neuronal pentraxin 1 contributes to the neuronal damage evoked by amyloid-beta and is overexpressed in dystrophic neurites in Alzheimer’s brain. J Neurosci 26:12735–12747
2. Baki L, Shioi J, Wen P, Shao Z, Schwarzman A, Gama-Sosa M, Neve R, Robakis NK (2004) PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J 23:2586–2596
3. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT (2010) Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68:19–31
4. Bi BT, Lin HB, Cheng YF, Zhou H, Lin T, Zhang MZ, Li TJ, Xu JP (2012) Promotion of beta-amyloid production by C-reactive protein and its implications in the early pathogenesis of Alzheimer’s disease. Neurochem Int 60:257–266
5. Bloom GS (2014) Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71:505–508
6. DaRocha-Souto B, Coma M, Perez-Nievas BG, Scotton TC, Siao M, Sanchez-Ferrer P, Hashimoto T, Fan Z, Hudry E, Barroeta I, Sereno L, Rodriguez M, Sanchez MB, Hyman BT, Gomez-Isla T (2012) Activation of glycogen synthase kinase-3 beta mediates beta-amyloid induced neuritic damage in Alzheimer’s disease. Neurobiol Dis 45:425–437
7. Datki Z, Juhasz A, Galfi M, Soos K, Papp R, Zadori D, Penke B (2003) Method for measuring neurotoxicity of aggregating polypeptides with the MTT assay on differentiated neuroblastoma cells. Brain Res Bull 62:223–229
8. Du Clos TW (2013) Pentraxins: structure, function, and role in inflammation. ISRN Inflamm 2013:379040
9. Duong T, Nikolaeva M, Acton PJ (1997) C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer’s disease. Brain Res 749:152–156
10. Eikelenboom P, van Exel E, Hoozemans JJ, Veerhuis R, Rozemuller AJ, van Gool WA (2010) Neuroinflammation - an early event in both the history and pathogenesis of Alzheimer’s disease. Neurodegener Dis 7:38–41
11. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140:918–934
12. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356
13. Heneka MT, O’Banion MK, Terwel D, Kummer MP (2010) Neuroinflammatory processes in Alzheimer’s disease. J Neural Transm 117:919–947
14. Hernandez P, Lee G, Sjoberg M, Maccioni RB (2009) Tau phosphorylation by cdk5 and Fyn in response to amyloid peptide Abeta (25–35): involvement of lipid rafts. J Alzheimers Dis 16:149–156
15. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology 73:768–774
16. Hoppe JB, Frozza RL, Horn AP, Comiran RA, Bernardi A, Campos MM, Battastini AM, Salbego C (2010) Amyloid-beta neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3beta, tau and neuroinflammation. J Pineal Res 48:230–238
17. Iwamoto N, Nishiyama E, Ohwada J, Arai H (1994) Demonstration of CRP immunoreactivity in brains of Alzheimer’s disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett 177:23–26
18. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM (2005) Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer’s disease. J Neurosci 25:8843–8853
19. Koh SH, Noh MY, Kim SH (2008) Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res 1188:254–262
20. Koide H, Asai T, Furuya K, Tsuzuku T, Kato H, Dewa T, Nango M, Maeda N, Oku N (2011) Inhibition of Akt (ser473) phosphorylation and rapamycin-resistant cell growth by knockdown of mammalian target of rapamycin with small interfering RNA in vascular endothelial growth factor receptor-1-targeting vector. Biol Pharm Bull 34:602–608
21. Li Y, Liu L, Barger SW, Griffin WS (2003) Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 23:1605–1611
22. Lin HB, Yang XM, Li TJ, Cheng YF, Zhang HT, Xu JP (2009) Memory deficits and neurochemical changes induced by C-reactive protein in rats: implication in Alzheimer’s disease. Psychopharmacology (Berl) 204:705–714
23. Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, Terro F (2013) Tau protein kinases: involvement in Alzheimer’s disease. Ageing Res Rev 12:289–309
24. McGeer EG, Yasojima K, Schwab C, McGeer PL (2001) The pentraxins: possible role in Alzheimer’s disease and other innate inflammatory diseases. Neurobiol Aging 22:843–848
25. Medina M, Avila J (2014) New perspectives on the role of tau in Alzheimer’s disease. Implications for therapy. Biochem Pharmacol 88:540–547
26. Nilsson L, Rogers J, Potter H (1998) The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer’s disease. Front Biosci 3:d436–d446
27. Osera C, Pascale A, Amadio M, Venturini L, Govoni S, Ricevuti G (2012) Pentraxins and Alzheimer’s disease: at the interface between biomarkers and pharmacological targets. Ageing Res Rev 11:189–198
28. Perry G, Roder H, Nunomura A, Takeda A, Friedlich AL, Zhu X, Raina AK, Holbrook N, Siedlak SL, Harris PL, Smith MA (1999) Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 10:2411–2415
29. Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP (2012) Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol Aging 33:427–431
30. Potter H, Wefes IM, Nilsson LN (2001) The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiol Aging 22:923–930
31. Quintanilla RA, Orellana DI, Gonzalez-Billault C, Maccioni RB (2004) Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 295:245–257
32. Schuitemaker A, Dik MG, Veerhuis R, Scheltens P, Schoonenboom NS, Hack CE, Blankenstein MA, Jonker C (2009) Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging 30:1885–1889
33. Takashima A (2006) GSK-3 is essential in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis 9:309–317
34. Tennent GA, Lovat LB, Pepys MB (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 92:4299–4303
35. Xu G, Zhou Z, Zhu W, Fan X, Liu X (2009) Plasma C-reactive protein is related to cognitive deterioration and dementia in patients with mild cognitive impairment. J Neurol Sci 284:77–80
36. Yasojima K, Schwab C, McGeer EG, McGeer PL (2000) Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease. Brain Res 887:80–89
37. Zhao R, Zhang Z, Song Y, Wang D, Qi J, Wen S (2011) Implication of phosphatidylinositol-3 kinase/Akt/glycogen synthase kinase-3beta pathway in ginsenoside Rb1’s attenuation of beta-amyloid-induced neurotoxicity and tau phosphorylation. J Ethnopharmacol 133:1109–1116
38. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA (2000) Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 59:880–888